Aryl dihydropyridinones and piperidinone MGAT2 inhibitors

A compound of Formula (II):

• or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
• R1 is independently selected from the group consisting of:
• C1-6 alkyl, C3-6 cycloalkyl, —CONHC4-18 alkyl, —CONHC2-8 haloalkyl, —CONH(CH2)1-8 Ph, —(CH2)m-(phenyl substituted with 1 Rb and 0-2 Rg), and a 5- to 6-membered heteroaryl substituted with 0-1 Rb and 0-2 Rg, wherein said heteroaryl is selected from:
• pyridyl, oxazolyl, thiazolyl and
• R2 is independently selected from the group consisting of:
• C1-4 alkyl and C1-4 haloalkyl;
• R3 is independently selected from the group consisting of:
• H and F;
• R4 is independently selected from the group consisting of:
• H and F;
• R6 is independently Rc or —(CH2)n—(X)t—(CH2)mRc;
• R11 and R15 are independently selected from the group consisting of:
• H, C1-4 alkyl and halo;
• R12 and R14 are independently selected from the group consisting of:
• H, halo, C1-4 alkyl and C1-4 alkoxy;
• R13 is independently selected from the group consisting of:
• H, halo, C1-4 alkyl substituted with 0-1 C1-4 alkoxy, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, —(CH2)m—C3-4 cycloalkyl, CN, N(C1-4 alkyl)2, NHCO2(C1-4 alkyl), NHSO2(C1-4 alkyl), pyrazolyl, and morpholinyl;
• alternatively, R12 and R13, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising:
• carbon atoms and 1-3 heteroatoms selected from N, NRe, O, and S;
• Rb is, at each occurrence, independently selected from the group consisting of:
• halo, OH, C1-8 alkyl, C1-8 alkoxy, C1-8 haloalkyl, C1-10 haloalkoxy, —O(CH2)sO(C1-6 alkyl), N(C1-4 alkyl)2, —CONH(CH2)6-20H, —(CH2)m(C3-6 cycloalkyl), —(CH2)m(C4-6 cycloalkenyl), —O(CH2)m(C3-6 cycloalkyl), 4-C1-4 alkoxy-Ph, —O(CH2)mPh, morpholinyl, pyridyl, 2-C1-4 alkoxy-pyridin-5-yl, pyrimidinyl, pyrazinyl, and —O-pyrimidinyl;
• Rc is, at each occurrence, independently selected from the group consisting of:
• C3-6 cycloalkyl substituted with 0-2 Rd, C3-6 cycloalkenyl substituted with 0-2 Rd, —(CH2)m-(phenyl substituted with 0-3 Rd), and a 5- to 6-membered heterocycle comprising:
• carbon atoms and 1-4 heteroatoms selected from N, NRe, O, and S;
• wherein said heterocycle is substituted with 0-2 Rd;
• Rd is, at each occurrence, independently selected from the group consisting of:
• halo, OH, CN, NO2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, tetrazolyl, OBn and phenyl substituted with 0-2 Rh;
• Re is, at each occurrence, independently selected from the group consisting of:
• H, C1-8 alkyl, C1-8 haloalkyl, benzyl optionally substituted with C1-4 alkoxy, CO(C1-4 alkyl) and COBn;
• Rf is, at each occurrence, independently selected from the group consisting of:
• H and C1-4 alkyl;
• Rg and Rh are, at each occurrence, independently selected from the group consisting of:
• halo, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy;
• n, at each occurrence, is independently 0 or 1;
• m, at each occurrence, is independently 0, 1, 2 or 3;
• s, at each occurrence, is independently 1, 2, or 3;
• and
• t, at each occurrence, is independently 0 or 1.